CA2370690A1 - Lipides peg cationiques et methodes d'utilisation - Google Patents

Lipides peg cationiques et methodes d'utilisation Download PDF

Info

Publication number
CA2370690A1
CA2370690A1 CA002370690A CA2370690A CA2370690A1 CA 2370690 A1 CA2370690 A1 CA 2370690A1 CA 002370690 A CA002370690 A CA 002370690A CA 2370690 A CA2370690 A CA 2370690A CA 2370690 A1 CA2370690 A1 CA 2370690A1
Authority
CA
Canada
Prior art keywords
lipid
cpl
peg
splp
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370690A
Other languages
English (en)
Inventor
Pieter R. Cullis
Tao Chen
David B. Fenske
Lorne R. Palmer
Kim Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370690A1 publication Critical patent/CA2370690A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Cette invention a trait à des conjugats polymère-lipide-cationique (CPL) tel que des conjugats poly(éthylène glycol)-lipide-cationique distaux pouvant être incorporés à des liposomes classiques ou à des liposomes furtifs ou à toute autre formulation à base de lipide pour renforcer l'absorption cellulaire. Les CPL selon l'invention comportent une fraction lipidique, un polymère hydrophile et une fraction polycationique. L'invention concerne également une méthode permettant de renforcer la libération intracellulaire d'acides nucléiques.
CA002370690A 1999-04-20 2000-04-20 Lipides peg cationiques et methodes d'utilisation Abandoned CA2370690A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13015199P 1999-04-20 1999-04-20
US60/130,151 1999-04-20
PCT/CA2000/000451 WO2000062813A2 (fr) 1999-04-20 2000-04-20 Lipides peg cationiques et méthodes d'utilisation

Publications (1)

Publication Number Publication Date
CA2370690A1 true CA2370690A1 (fr) 2000-10-26

Family

ID=22443303

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370690A Abandoned CA2370690A1 (fr) 1999-04-20 2000-04-20 Lipides peg cationiques et methodes d'utilisation

Country Status (5)

Country Link
EP (1) EP1173600A2 (fr)
JP (2) JP5117648B2 (fr)
AU (1) AU783647B2 (fr)
CA (1) CA2370690A1 (fr)
WO (1) WO2000062813A2 (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69841002D1 (de) 1997-05-14 2009-09-03 Univ British Columbia Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
US7189705B2 (en) 2000-04-20 2007-03-13 The University Of British Columbia Methods of enhancing SPLP-mediated transfection using endosomal membrane destabilizers
EP1355670A2 (fr) * 2000-04-20 2003-10-29 University of British Columbia Procedes permettant d'ameliorer la transfection a mediation splp (particule plasmide-lipide stabilisee) au moyen de destabilisateurs de la membrane endosomale
AU2002214854A1 (en) * 2000-10-25 2002-05-06 Inex Pharmaceuticals Corporation Lipid formulations for target delivery
US6610322B1 (en) * 2000-12-20 2003-08-26 Brian Charles Keller Self forming, thermodynamically stable liposomes and their applications
US7901708B2 (en) 2002-06-28 2011-03-08 Protiva Biotherapeutics, Inc. Liposomal apparatus and manufacturing methods
WO2004082626A2 (fr) * 2003-03-18 2004-09-30 Ethicon, Inc. Diagnostic et traitement faisant appel a un inhibiteur de l'aromatase
CA2532228C (fr) 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Arn interferant encapsule dans un lipide
EP1664316B1 (fr) * 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Composes lipidiques modifies avec du polyethyleneglycol et utilisations de ces composes
FR2870741B1 (fr) * 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
AU2005252273B2 (en) 2004-06-07 2011-04-28 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US8765181B2 (en) * 2005-09-09 2014-07-01 Beijing Diacrid Medical Technology Co., Ltd Nano anticancer micelles of vinca alkaloids entrapped in polyethylene glycolylated phospholipids
CN101346393B (zh) 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
JP5697988B2 (ja) 2007-12-27 2015-04-08 プロチバ バイオセラピューティクス インコーポレイティッド 干渉ｒｎａを使用したポロ様キナーゼ発現のサイレンシング方法
WO2009129319A2 (fr) 2008-04-15 2009-10-22 Protiva Biotherapeutics, Inc. Réduction au silence de l'expression du gène csn5 au moyen d'arn interférant
ES2638448T3 (es) 2008-04-15 2017-10-20 Protiva Biotherapeutics Inc. Novedosas formulaciones de lípidos para la administración de ácidos nucleicos
WO2009129227A1 (fr) 2008-04-17 2009-10-22 Pds Biotechnology Corporation Stimulation de réponse immunitaire par des énantiomères de lipides cationiques
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US8283333B2 (en) 2009-07-01 2012-10-09 Protiva Biotherapeutics, Inc. Lipid formulations for nucleic acid delivery
US8716464B2 (en) 2009-07-20 2014-05-06 Thomas W. Geisbert Compositions and methods for silencing Ebola virus gene expression
EP2480668A2 (fr) 2009-09-23 2012-08-01 Protiva Biotherapeutics Inc. Compositions et procédés pour réduire au silence des gènes exprimés dans le cancer
TR201901311T4 (tr) 2009-12-01 2019-02-21 Translate Bio Inc İnsan genetik hastalıklarında mRNA'nın teslimi için steroid türevi.
WO2011141704A1 (fr) 2010-05-12 2011-11-17 Protiva Biotherapeutics, Inc Nouveaux lipides cationiques cycliques et procédés d'utilisation
JP2013527856A (ja) 2010-05-12 2013-07-04 プロチバ バイオセラピューティクス インコーポレイティッド 陽イオン性脂質およびその使用方法
JP2013530187A (ja) 2010-06-17 2013-07-25 ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンティッド バイ ザ シークレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ 炎症性疾患を治療するための組成物及び方法。
WO2012000104A1 (fr) 2010-06-30 2012-01-05 Protiva Biotherapeutics, Inc. Systèmes non liposomaux pour une administration d'acide nucléique
BR112013031553A2 (pt) 2011-06-08 2020-11-10 Shire Human Genetic Therapies, Inc. composições, mrna que codifica para uma hgla e seu uso, uso de pelo menos uma molécula de mrna e um veículo de transferência e uso de um mrna que codifica para proteína exógena
US11073451B2 (en) 2011-12-19 2021-07-27 Kode Biotech Limited Biocompatible method of functionalising substrates with inert surfaces
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
RU2020111326A (ru) 2012-02-24 2020-04-29 Протива Байотерапьютикс Инк. Триалкил катионные липиды и способы их использования
SG10201610401XA (en) * 2012-03-16 2017-01-27 Merck Patent Gmbh Targeting aminoacid lipids
WO2013185067A1 (fr) 2012-06-08 2013-12-12 Shire Human Genetic Therapies, Inc. Polynucléotides résistant à la nucléase et leurs utilisations
EP4091630A1 (fr) 2012-09-21 2022-11-23 PDS Biotechnology Corporation Vaccins contenant du r-dotap
SG11201507425RA (en) 2013-03-14 2015-10-29 Shire Human Genetic Therapies Methods for purification of messenger rna
CN105142676B (zh) 2013-03-14 2022-06-28 夏尔人类遗传性治疗公司 Cftr mrna组合物以及相关方法和用途
EP3033325B1 (fr) 2013-07-23 2019-12-04 Arbutus Biopharma Corporation Compositions et procédés pour l'administration d'arn messager
EP3060258A1 (fr) 2013-10-22 2016-08-31 Shire Human Genetic Therapies, Inc. Thérapie à l'arnm pour la phénylcétonurie
EP3501605B1 (fr) 2013-10-22 2023-06-28 Translate Bio, Inc. Thérapie arnm pour déficience en argininosuccinate synthétase
JP6571679B2 (ja) 2014-04-25 2019-09-04 トランスレイト バイオ， インコーポレイテッド メッセンジャーｒｎａの精製方法
BR112017006679A2 (pt) 2014-10-02 2017-12-26 Protiva Biotherapeutics Inc moléculas, composição, partícula, composição farmacêutica, métodos para silenciar a expressão de um gene, usos de uma partícula, métodos para melhorar um ou mais sintomas, métodos para tratar uma infecção, usos de uma composição, método para inibir a replicação do vírus da hepatite d
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
CN108350455A (zh) 2015-07-29 2018-07-31 阿布特斯生物制药公司 用于使b型肝炎病毒基因表达沉默的组合物和方法
WO2017035278A1 (fr) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Nanoparticules polynucléotidiques pour la modulation de l'expression génique et leurs utilisations
US11612652B2 (en) 2015-11-13 2023-03-28 Pds Biotechnology Corporation Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy
US11191849B2 (en) 2016-06-30 2021-12-07 Arbutus Biopharma Corporation Compositions and methods for delivering messenger RNA
AU2018224326B2 (en) 2017-02-27 2024-01-04 Translate Bio, Inc. Novel codon-optimized CFTR mRNA
MA49138A (fr) 2017-05-16 2020-03-25 Translate Bio Inc Traitement de la fibrose kystique par administration d'arnm à codons optimisés codant pour la cftr
CN112930396B (zh) 2018-08-24 2024-05-24 川斯勒佰尔公司 用于纯化信使rna的方法
GB201910299D0 (en) 2019-07-18 2019-09-04 Aouadi Myriam Medical uses, methods and uses
CA3162374A1 (fr) * 2019-12-20 2021-06-24 So Jin Lee Kit de preparation de composition de nanoparticules servant a l'administration de medicament, comprenant un sel d'acide polylactique
KR20220154740A (ko) 2020-03-17 2022-11-22 제네반트 사이언시즈 게엠베하 간 성상 세포로 치료제의 지질 나노입자 전달을 위한 양이온성 지질
US11591544B2 (en) 2020-11-25 2023-02-28 Akagera Medicines, Inc. Ionizable cationic lipids
AU2023214198A1 (en) 2022-01-31 2024-08-15 Genevant Sciences Gmbh Ionizable cationic lipids for lipid nanoparticles
US12064479B2 (en) 2022-05-25 2024-08-20 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids and methods of use thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1444991A1 (fr) * 1995-06-07 2004-08-11 Imarx Pharmaceutical Corp. Compositions ciblées à application diagnostique et thérapeutique
EP0932390A1 (fr) * 1996-10-11 1999-08-04 Sequus Pharmaceuticals, Inc. Composition de liposomes therapeutiques et procede
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
WO1998046208A1 (fr) * 1997-04-17 1998-10-22 The Regents Of The University Of Michigan Systeme de delivrance d'adn de follicule pileux
AU7490098A (en) * 1997-05-15 1998-12-08 Genzyme Corporation Cationic amphiphile formulations
US6395713B1 (en) * 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
US6110745A (en) * 1997-07-24 2000-08-29 Inex Pharmaceuticals Corp. Preparation of lipid-nucleic acid particles using a solvent extraction and direct hydration method
AU4698499A (en) * 1998-06-19 2000-01-05 Genzyme Corporation Cationic amphiphile micellar complexes
AU2620000A (en) * 1999-01-21 2000-08-07 Georgetown University Ligand-peg post-coating stabilized lipoplex and polyplex for targeted gene delivery
EP1046394A3 (fr) * 1999-04-19 2001-10-10 ImaRx Pharmaceutical Corp. Nouvelles compositions utilisables pour la délivrance de composés dans une cellule
US6926884B2 (en) * 2000-03-02 2005-08-09 Mitsubishi Pharma Corporation GPIb-lipid bond construct and use thereof

Also Published As

Publication number Publication date
JP5117648B2 (ja) 2013-01-16
JP2002542341A (ja) 2002-12-10
WO2000062813A2 (fr) 2000-10-26
AU783647B2 (en) 2005-11-17
AU4096200A (en) 2000-11-02
EP1173600A2 (fr) 2002-01-23
WO2000062813A3 (fr) 2001-08-09
JP2012122075A (ja) 2012-06-28

Similar Documents

Publication Publication Date Title
AU783647B2 (en) Cationic peg-lipids and methods of use
US6852334B1 (en) Cationic peg-lipids and methods of use
US6320017B1 (en) Polyamide oligomers
EP1328254B1 (fr) Formulations de lipides pour une administration ciblee
EP0783297B1 (fr) Lipides du type ceramide modifies par polyethylene glycol et de liposomes
US6815432B2 (en) Methods for encapsulating plasmids in lipid bilayers
EP1041976B1 (fr) Oligomeres polyamidiques
US6986902B1 (en) Polyanionic polymers which enhance fusogenicity
WO2002087541A1 (fr) Formulations a base de lipides pour transfert genique
Nicolazzi et al. Cationic lipids for transfection
EP1664316A1 (fr) Composes conjugues lipidiques polyethyleneglycol modifies et utilisations de ces composes
WO2006007712A1 (fr) Methodes permettant de distribuer des agents therapeutiques comprenant des conjugues de lipide-polyethylene glycol
Koynova et al. Recent patents in cationic lipid carriers for delivery of nucleic acids
KR100723852B1 (ko) 핵산 및 약물 전달용 중성-양이온성 지질
JP2004508012A (ja) エンドソーム膜不安定剤を用いたｓｐｌｐ媒介性トランスフェクションの強化方法
EP1100834B1 (fr) polymères polyanioniques à fusogénicité améliorée
Martin et al. Advances in cationic lipid-mediated gene delivery
AU8006400B2 (fr)
AU2773902A (en) Polyamide oligomers

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead